



Updated Monthly

October 11, 2026

Prepared for:



THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:



Questions?

Liz Powell, Esq., MPH
lpowell@G2Gconsulting.com
www.G2Gconsulting.com

  @G2Gconsulting





TABLE OF CONTENTS

New Opportunities

Aging.....	2
Amyotrophic Lateral Sclerosis	3
Artificial Intelligence & Machine Learning	3
Autism.....	4
Bioengineering.....	4
Biomedical Research.....	5
Cancer	7
Chronic Disease	8
Chronic Pain & Pain Management	8
Clinical Trials	8
Cognitive and Brain Health.....	10
Diagnostics	10
Genomics	11
Health IT & Data	12
HIV/AIDS	12
Immunology & Infectious Disease	13
Maternal and Pediatric Health	15
Medical Countermeasures.....	16
Musculoskeletal Health	16

GBG Report

Updated Monthly

October 11, 2026

<https://www.g2gconsulting.com/gbg-reporting-service/>

Small Business Development.....	17
Substance Use Disorder	17
Therapeutics	18
Toxic Exposures.....	18
Vision Research.....	19

Recurring Opportunities

Advanced Research Projects Agency for Health	20
Air Force	21
Army	22
BARDA.....	24
DARPA.....	24
Defense Threat Reduction Agency.....	25
Department of Energy	26
National Science Foundation	26
Navy.....	27
Office of the Undersecretary of Defense	27
Patient-Centered Outcomes Research Institute	28

GBG Acronyms	30
---------------------------	-----------



October 15, 2026 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EST (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you’re an affiliate of Biocom, BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Life Sciences Association, Georgia Life Sciences, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, VaBio, or BioWV – your membership gets you access to the [private consultation meeting](#).

November 6, 2026 – Join G2G and grIP Venture Studio for the next [What’s Happening in Washington, DC](#) webinar. This is a quarterly series where insiders share their perspectives on issues ranging from the economy to politics to government funding and policy priorities. Coming just days after the 2026 midterms, we will discuss what the election results and the composition of the 120th Congress could portend for the federal bioscience landscape. Register [here](#)!

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING (4)		
1.	Forecast: Continuation of the Exceptional Longevity Data Management and Coordinating Center (EL DMCC) (U24 Clinical Trial Not Allowed) (NIH/NIA) RFA-AG-27-004	The EL DMCC serves as the central hub for NIA’s human longevity translational research portfolio, integrating data and activities across studies to maximize the value of deeply phenotyped cohorts and associated genomic and multi-omics datasets. The DMCC currently plays a critical role in enabling cross-cohort analyses, coordinating collaborative research, and advancing shared data resources. Core functions include data harmonization and integration; development and implementation of common data standards; provision of statistical, computational, and AI/ML infrastructure and tools; coordination of cross-project collaborations; and managing shared data systems, including data storage, access, and platform operations. https://www.grants.gov/search-results-detail/363945	TBD	Estimated post date: 2/8/27 Estimated due date: 5/8/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING		
2.	Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs); Discovery, Validation Centers; and SenNet Data Coordination and Integration Center (SenNet DCIC) (UG3/UH3/UM1 Clinical Trial Not Allowed) (NIH Common Fund) RFA-RM-27-007 (UG3/UH3) RFA-RM-27-016 (UM1) RFA-RM-27-025 (UM1)	These NOFOs: solicit the development of innovative senescence technologies (SenTecs), or the adaptation of existing technologies focused on identification, characterization and understanding the biological consequences of senescent cell (SnC) heterogeneity in the context of the tissue environments and secretomes to facilitate novel strategies for modulating SnCs in vivo and for predicting the outcomes of targeting SnCs in human aging and in disease conditions; support SenNet DVCs and SenNet DCIC. https://www.grants.gov/search-results-detail/359168 (UG3/UH3) https://www.grants.gov/search-results-detail/359169 (UM1) https://www.grants.gov/search-results-detail/361817 (UM1)	Up to \$400,000 per year (UG3) Up to \$550,000 per year (UH3) Up to \$3 million per year, for up to 5 years (UM1)	Proposal: 11/23/26
		AMYOTROPHIC LATERAL SCLEROSIS (1)		
3.	Forecast: Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) (NIH/NINDS) RFA-NS-28-009	Eligible intermediate expanded access protocols for ALS should: 1) provide access to an investigational drug or biological product for people with ALS, and 2) generate data to support research on the prevention, diagnosis, mitigation, treatment, or cure of ALS. https://www.grants.gov/search-results-detail/363926	TBD	Estimated post date: 3/1/27 Estimated due date: 5/25/27
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (3)		
4.	NSF X-Labs Initiative – AI for Physical Systems Topic Announcement (NSF) NSF-Topic3-FY26-XLabsPhysicalAI	NSF seeks innovative, early stage platform technologies that advance intelligent, adaptive, and scalable AI systems operating in or interfacing with the physical world, including robotics, embodied systems, human robot interfaces, advanced sensing, and cyber physical systems. https://sam.gov/workspace/contract/opp/36caccb7f3784342812ab25b8d48fa5d/view	Dependent upon proposal and available funds	Proposal: 1/7/27
5.	Documentation and Decision Support Sprint (DoD/DARPA)	The D2 Sprint tasks teams from across the country to create AI tools capable of automatically assessing casualties, recommending treatments, guiding care, and seamlessly documenting the process. Through a series of demanding evaluations, this event will push the state-of-the-art in artificial intelligence and medical informatics. The innovations spurred by the challenge will ensure our warfighters have access to guided, high-quality medical support at the point of injury, while capturing the critical data needed for long-term patient recovery. https://centralfloridatechgrove.org/darpa-d2-sprint/	Total prizes of \$1 million	Application: 12/1/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING		
6.	Military Injury Cause Coding (MTEC)	This RFI is focused on surveying the current state of developing, testing, and implementing AI-driven processes aimed at improving EHR injury cause coding without overburdening those responsible for documenting military injuries. Solutions should minimize workflow disruption while improving coding completeness, specificity, accuracy, and consistency. The Government is interested in approaches that support clinician decision-making and documentation efficiency rather than increasing manual data entry requirements. https://mtec-sc.org/solicitations/MTEC-26-04-MICC	N/A	Response: 10/16/26
		AUTISM (1)		
7.	Systems for Phenotypic Evaluation, Clinical Trajectories, Response, and Agency (SPECTRA) (ARPA-H) ARPA-H-SOL-26-163	The SPECTRA (Systems for Phenotypic Evaluation, Clinical Trajectories, Response, and Agency) program takes a bold approach, anchoring autism research in objective, multi-factor measurement and computation rather than behavioral observation alone. The program is built on the hypothesis that nonlinear interactions among genetic, environmental, family, metabolic, immune, microbiome, and developmental factors shape distinct developmental, health, communication, and functional trajectories. To achieve the goals of this program, ARPA-H seeks bold, cross-disciplinary solutions across four technical areas (TAs): Analysis, Modeling, Precision Intervention, and Enabling Technologies. https://arpa-h.gov/explore-funding/programs/spectra https://sam.gov/workspace/contract/opp/ae0ce5edc4c341afbf26a9413cfd6e62/view	Dependent upon proposal and award mechanism	Solution summary: 10/18/26 (TA4) 12/2/26 (TA 1 & 2) 1/18/27 (TA 3)
		BIOENGINEERING (2)		
8.	UNifying Imaging with QUantum Entanglement (UNIQUE) Innovative Solutions Opening (ISO) (ARPA-H) ARPA-H-SOL-26-162	UNIQUE seeks cross-disciplinary performer teams with expertise spanning quantum science, radiological sciences, biomedical imaging, engineering, materials science, computational modeling, and AI-based reconstruction and interpretation. Teams should be able to both measure quantum-derived observables and interpret them as meaningful biomedical imaging signals. UNIQUE has two technical areas: Imaging Core and Quantum AI Interpretation and Fusion. https://arpa-h.gov/explore-funding/programs/unique https://sam.gov/workspace/contract/opp/b656f68a72844aa6b6013ad9295625c7/view	Dependent upon proposal and award mechanism	Proposers' Day: 10/16/26 Solution Summary: 10/29/26 Proposal: 12/15/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOENGINEERING		
9.	Autonomous Surgery Challenge (DoD/DARPA)	The DARPA Surgical Competition (DSC) seeks to accelerate the development of autonomous robotic systems for trauma surgery. The Surgical Competition calls on teams from across the world to create robotic systems capable of assisting and, eventually, independently performing complex surgical procedures in unpredictable trauma environments. The goal is to assist human surgeons, creating a force multiplier that provides "infinite" surgical capacity on demand. https://centralfloridatechgrove.org/darpa-surgical-competition/	Total prizes of \$3.5 million	Application: 10/30/26
		BIOMEDICAL RESEARCH (9)		
10.	ARPA-H Emerging Health Innovators (EHI) Initiative (ARPA-H) ARPA-H-SOL-26-150	ARPA-H's EHI Initiative aims to increase access to government research funding and to seed new ideas that address healthcare gaps in the United States. The 2026 cycle will seek proposals across these topic areas: Precision Control of Skin Inflammation without Systemic Exposure; Internal Sensing and Targeted Control of Inflammation; Host-Pathway Interventions for Neurotropic Disease (HIND); Ending Preventable Deaths from Ectopic Pregnancy Through First-Visit Diagnosis; Transforming the Well-Woman Exam through Objective Data; Innovations in Biotransport to Support Long-Term Preservation of Tissues and Organs; Organs-in-Action: Next-Generation Human Tissue Platforms for Longevity, Disease, and Therapy Discovery; and ICAT (In-Cavity Adjuvant Therapy): Implantable Systems for Local Cancer Control at the Resection Margin. https://arpa-h.gov/explore-funding/programs/ehi https://sam.gov/workspace/contract/opp/97049f3d1bb44fa292b998d15ce99c6a/view	Dependent upon proposal and award mechanism	Proposers' Day: 10/13/26 Solution Summary: 10/30/26 Proposal: 2/10/27
11.	High-throughput Unmasking of Biological Interactomes with Binding Landscape Emulators (HUBBLE) Proposers' Day (DoD/DARPA) DARPA-PA-27-01	HUBBLE seeks to generate a comprehensive human interactome that represents both healthy and disrupted physiologies. To overcome time and resource limits of experimentally resolving or atomistically simulating these interactions, HUBBLE will generate low-dimensional signatures of each protein interaction based on the topology of its diffusive binding landscape. By leveraging dimensionality reducing simulation methods, HUBBLE performers can generate signature libraries from established databases as a launching point prior to embarking on resolving "dark interactome". By end of program HUBBLE will generate a hypercatalog of context-aware interactions with predicted probabilities, affinities, and kinetics that are specific to the cell types, and conditions in which they occur. https://sam.gov/opp/98c034706e4b430281ead1c3497e9d72/view	Dependent upon proposal and available funds	Abstract: 11/5/26 Oral Proposal: 12/11/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH		
12.	Fiscal Year 2026 Multi-Topic Request for Project Proposals (MTEC) MTEC-26-04-MultiTopic	This RPP solicits a broad range of medical prototype technological and knowledge solutions related to the 16 Focus Areas of Interest. Amendment No. 1 added a new Focus Area 16: Multisite Clinical Biomarker Platform for Trauma-Related Lung and Kidney Failure. https://mtec-sc.org/solicitations/multitopic-26	Dependent upon focus area and proposal, for up to 3 years	Enhanced White Paper: 10/30/26
13.	Forecast: Research to Improve Rigor, Replicability, and Reproducibility in Biomedical and Behavioral Sciences (NIH/NINDS) PAR-28-061	This NOFO will support research projects that directly improve or evaluate biomedical and behavioral rigor, replicability, and reproducibility. Example projects include, but are not limited to: Assessing the scientific and behavioral impact of improving rigor, replicability, and reproducibility; Developing decision-making frameworks to select candidate studies for replication with the highest potential for scientific value or novel insights; Measuring replicability, reproducibility, robustness, and generalizability of important research findings to accelerate scientific innovation. https://www.grants.gov/search-results-detail/363915	TBD	Estimated post date: 4/23/27 Estimated due date: 5/25/27
14.	Forecast: Development of Models, New Approach Methodologies, and Biological Materials for Studying Human Health and Diseases (R21 Clinical Trial Not Allowed) (NIH/ORIP) PAR-29-002	This NOFO will encourage innovative research to develop, characterize, improve or preserve research models and model related biological materials, and to develop or improve technologies, including new approach methodologies (NAMs), for studies relevant to human health and diseases. This NOFO also seeks projects aimed at improving the identification and control of factors that could confound or interfere with the use of research models in biomedical research. https://www.grants.gov/search-results-detail/363877	Up to \$500,000	Estimated post date: 12/16/27 Estimated due date: 2/16/28
15.	Forecast: R3PEATS Grassroots Rigor Projects: Individual Metascience and Individual Laboratory Capacity-Building (RP1); R3PEATS Multi-Team Triangulation: Collaborative Cross-Method Approaches to Scientific Discovery (RM1); and R3PEATS Rigor Scholar Cohort (NIH Common Fund) RFA-RM-28-011 (RP1) RFA-RM-28-012 (RM1) RFA-RM-28-013 (K12)	R3PEATS Multi-Team Triangulation supports coordinated teams to investigate a central biomedical research question through complementary methods, model systems, or populations. R3PEATS Grassroots Rigor Projects supports two project types that generate practical tools and shared knowledge to strengthen research practices. Rigor Scholar Cohort Awards support early-career researchers to advance expertise in rigorous scientific practices, such as preregistration, blinding, randomization, and transparent dissemination, through multi-institutional collaboration. https://www.grants.gov/search-results-detail/363849 (RP1) https://www.grants.gov/search-results-detail/363850 (RM1) https://www.grants.gov/search-results-detail/363851 (K12)	Total funding of \$5.6 million (RP1) Total funding of \$5 million (RM1) Total funding of \$4.25 million (K12)	Estimated post date: 7/1/27 Estimated due date: 10/1/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH		
16.	Blueprint MedTech Incubator Hub Cycle 7 Funding Solicitation (NIH)	This program will catalyze the translation of novel technologies from proof-of-concept to a prototype ready for first-in-human testing and will provide: (a) non-dilutive funds to support medical device development activities, and (b) ongoing, specialized support from experienced executive mentors. The NIH-funded Blueprint MedTech Incubator program will provide funding, mentoring, oversight, and in-kind resources to innovator teams. The objective of Hub support is to further develop and de-risk these groundbreaking technologies to the point of readiness for first-in-human testing. https://blueprintneurotech.org/	Up to \$1.28 million	Pre-proposal: 10/21/26 Full Proposal: 12/21/26
		CANCER (6)		
17.	Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional) and Management and Data Coordination Unit (U24 Clinical Trial Not Allowed) (NIH/NCI) PAR-28-056 (U01) PAR-28-057 (U24)	The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; develop molecular- and/or imaging-based markers of pancreatic cysts and determine which lesions are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-MDCU will provide support towards collaborative efforts such as study design, protocol development, statistical analysis, coordination and data management. https://www.grants.gov/search-results-detail/361275 (U01) https://www.grants.gov/search-results-detail/361276 (U24)	Up to \$600,000 per year for up to 5 years (U01) Up to \$500,000 per year for up to 5 years (U24)	Multiple deadlines; NOFO open through 11/5/29 (U01) Multiple deadlines; NOFO open through 5/25/27 (U24)
18.	Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed) (NIH/NCI) RFA-CA-28-013	NCI seeks meritorious proposals to critically and systematically evaluate the scientific evidence on carcinogenic hazards to humans. Identifying potential carcinogens is essential for guiding and advancing cancer research, as well as informing cancer control and prevention efforts. https://www.grants.gov/search-results-detail/360905	Up to \$700,000 per year, for up to 5 years	Proposal: 2/9/27
19.	Gateway for Cancer Research Grant Programs (Gateway)	Gateway exclusively funds Phase I and Phase II research trials, which often mark the first-in-human study of promising new cancer drugs and therapies. This includes rare cancers for which funding is scarce as well as some of the most prevalent cancers affecting men, women and children today. https://gatewaycr.smapplly.org/prog/gfcr_all_grant_programs_-_v122023/	Up to \$1.5 million, for up to 5 years	Letter of intent: 11/6/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
20.	Targeted Cancer Grand Challenges On Gastroesophageal Cancers (CRUK/TCF/GEMINI)	Cancer Research UK and the Torrey Coast Foundation have partnered to launch a targeted Cancer Grand Challenges funding call on gastroesophageal cancers and seek to fund international teams capable of bringing novel approaches, technologies and thinking to tackle two major challenges. Challenge 1: Understand and reverse early tissue changes leading to gastroesophageal cancers; Challenge 2: Determine the biological mechanisms underpinning geographical variations in gastroesophageal cancer incidence. https://www.cancergrandchallenges.org/apply-for-a-challenge		Letter of interest: 11/10/26 Proposal: 11/24/26
		CHRONIC DISEASE (1)		
21.	Forecast: Chronic Disease Education and Awareness (CDC/NCCDPHP) CDC-RFA-DP-27-0068	This NOFO will support organizations to strengthen national chronic disease education and awareness for chronic diseases that are not supported through disease-specific CDC funding by implementing activities that enhance surveillance, address priority evidence gaps, develop and disseminate evidence-based educational resources, strengthen strategic partnerships, and promote the adoption of evidence-based prevention, screening, referral, treatment, disease management, and self-management practices. https://www.grants.gov/search-results-detail/364055	Total funding of \$15 million	Estimated post date: 3/1/27 Estimated due date: 4/30/27
		CHRONIC PAIN & PAIN MANAGEMENT (1)		
22.	HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required) (NIH/NCCIH) PAR-27-045	The goal of this NOFO is to advance the mechanistic understanding of interactions across these tissues and systems that together define the "whole joint" as one integrated organ. As such, this NOFO will support studies that identify and measure whole joint mechanisms, including at least one periarticular tissue and interactions with one or more articular tissues or peripheral physiological or neural systems. This NOFO will support studies that first examine how these interactions contribute to joint pain and reduced whole joint health and then determine how interventions modify mechanisms across multiple tissues and pathways to restore whole joint health. https://www.grants.gov/search-results-detail/361304	Dependent upon proposal, for up to 5 years	Proposal: 10/30/26
		CLINICAL TRIALS (7)		
23.	Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) (ARPA-H) ARPA-H-SOL-26-164	SURPASS seeks to build perpetual, adaptive platform trials that combine predictive computational models, shared trial infrastructure, common control groups, and real-time analysis to enable earlier, smarter decision making that will help speed effective drugs to patients. https://arpa-h.gov/explore-funding/programs/surpass https://sam.gov/workspace/contract/opp/11128fed4f044b68a9185dada11c90d9/view	Dependent upon proposal and award mechanism	Proposers' Day: 11/6/26 Solution Summary: 11/30/26 Proposal: 1/22/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CLINICAL TRIALS		
24.	Forecast: Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required) (NIH) PAR-28-074	This NOFO will solicit applications that propose early to definitive clinical trials. Trials testing drugs, devices, biologics, procedures, behavioral, social, economic, health services, or other biomedical or non-pharmacological interventions are of interest to this initiative. https://www.grants.gov/search-results-detail/363991	TBD	Estimated post date: 5/31/27 Estimated due date: 7/31/27
25.	Forecast: Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) Infrastructure – Clinical Coordinating Center (CCC) & Data Coordinating Center (DCC) and Clinical Research Sites (U24 Clinical Trial Not Allowed) (NIH/NINDS) RFA-NS-28-002 RFA-NS-28-007 (U24)	NeuroNEXT conducts clinical trials and biomarker validation studies for neurological disorders in adult and pediatric populations. By offering infrastructure, expertise, and collaborative opportunities, NeuroNEXT accelerates innovation and impact, advancing the development of safe, effective neurotherapeutics for patients through high-quality evidence pathways. These NOFOs will encourage applications for a Clinical Coordinating Center (CCC), Data Coordinating Center (DCC), and network clinical research sites to support NeuroNEXT. https://www.grants.gov/search-results-detail/363839 https://www.grants.gov/search-results-detail/363835 (U24)	TBD	Estimated post date: 9/1/27 Estimated due date: 11/1/27
26.	Forecast: NIH Stroke Clinical Trials Network (StrokeNet) Infrastructure – National Coordinating Center (NCC), National Data Management Center (NDMC), and Regional Coordinating Stroke Centers (RCCs) (NIH/NINDS) RFA-NS-28-003 RFA-NS-28-008	The NIH StrokeNet conducts clinical trials focused on advancing acute stroke treatment, stroke prevention, and stroke recovery and rehabilitation across the lifespan. Its mission is to improve outcomes for individuals who experience stroke by evaluating promising new therapies for patients with stroke and those at risk for stroke. The program will encourage applications for a national clinical coordinating center (NCC), national data management coordinating center (NDMC), and network regional clinical enrollment coordinating centers (RCCs). https://www.grants.gov/search-results-detail/363841 https://www.grants.gov/search-results-detail/363838	TBD	Estimated post date: 12/20/27 Estimated due date: 1/25/28
27.	Forecast: BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (NIH/NINDS) RFA-NS-28-006	This NOFO will encourage investigators to pursue first-in-human or early-stage clinical studies for recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain. This NOFO will be a part of a milestone-driven program, involving collaborative activities with the program officer(s)/director(s) assigned to the funded projects and joint responsibility for the successful management of the program post-award. https://www.grants.gov/search-results-detail/363840	Total funding of \$10 million	Estimated post date: 12/10/26 Estimated due date: 1/28/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH (2)		
28.	Forecast: Limited Competition: BRAIN Initiative: Promoting Health for All Through BRAIN Technology Partnerships (NIH/NINDS) RFA-NS-28-005	This NOFO will solicit applications to accelerate the scientific impact and broad research adoption of BRAIN Initiative-relevant neurotechnologies at institutions with limited NIH Research Project Grant funding. This opportunity will enable the integration of these neurotechnologies into the research and/or training programs of investigators at institutions with limited NIH Research Project Grant funding, while expanding the dissemination of BRAIN-initiative technologies. https://www.grants.gov/search-results-detail/363848	TBD	Estimated post date: 1/9/27 Estimated due date: 6/17/27
29.	BRAIN Initiative: Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (R01 Clinical Trial Not Allowed) (NIH) RFA-NS-28-010	This funding opportunity supports transformative, mechanistic research aimed at understanding how the human brain functions. Applications should seek to reveal how the dynamic activity of individual neurons and ensembles of neurons within spatially organized brain networks gives rise to internal experiences, such as sensations, perceptions, emotions, thoughts, and memories, as well as to observable motor and social behaviors. https://www.grants.gov/search-results-detail/360402	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 2/8/29
		DIAGNOSTICS (4)		
30.	Forecast: Undiagnosed Diseases Network (UDN) Clinical and Data Coordinating Center, Diagnostic Research Innovation Center, and Clinical Networks of Diagnostic Excellence (NIH/NINDS) PAR-27-135 PAR-27-136 PAR-27-137	NINDS intends to support a new phase of the Undiagnosed Diseases Network (UDN) to advance diagnosis for individuals with previously undiagnosed diseases and undiagnosed diseases research. The CDCC will provide operational oversight and coordination. The DRIC is expected to test and advance innovative, new diagnostic tools and strategies for both genomic and non-genomic conditions. Clinical NODEs are expected to provide a coordinated, multidisciplinary and participant-centered evaluation of individuals with highly challenging, difficult-to-diagnose conditions. https://www.grants.gov/search-results-detail/363836 https://www.grants.gov/search-results-detail/363837 https://www.grants.gov/search-results-detail/363834	TBD	Estimated post date: 3/25/27 Estimated due date: 5/25/27
31.	RADx® Tech Independent Test Assessment Program for Mycobacterium Tuberculosis Complex Near-patient* and/or Lab-based Diagnostics (NIH/NIBIB/RADx)	RADx is soliciting proposals to accelerate the validation, 510(k) submission, and commercialization of near-patient and/or lab-based molecular tests that can detect, at-minimum, Mycobacterium tuberculosis complex. Ideally, the diagnostic test would also include targets for detection of mutations associated with resistance to at least rifampicin with a desire for additional targets covering other drugs/drug classes including isoniazid and fluoroquinolones. https://cimit.org/radx-tech-itap-mycobacterium-tuberculosis-complex/	TBD	Proposal: 10/29/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		GENOMICS (8)		
32.	Impact of Genomic Variation on Function (IGVF) Consortium (UM1/U24 Clinical Trials Not Allowed) (NIH/NHGRI) RFA-HG-27-007 (UM1) RFA-HG-27-008 (U24) RFA-HG-27-009 (UM1) RFA-HG-27-010 (UM1)	The Impact of Genomic Variation on Function Consortium (IGVF) was established in 2021 to address the challenge of understanding how genomic variation affects genome function to influence phenotypes using a coordinated team-science approach. The goals of the second phase of IGVF are to: Test the impact of individual genomic variants on function; Study the effects of genomic variant interactions on function; Model and predict the impacts of genomic variation on function and phenotype; and Expand a set of resources to enable future studies. https://www.grants.gov/search-results-detail/358854 (UM1) https://www.grants.gov/search-results-detail/358855 (U24) https://www.grants.gov/search-results-detail/359277 (UM1) https://www.grants.gov/search-results-detail/359170 (UM1)	Up to \$2 million per year, for up to 5 years (UM1) Up to \$4 million per year, for up to 5 years (U24) Up to \$1.5 million per year, for up to 5 years (UM1) Up to \$800,000, for up to 5 years (UM1)	Proposal: 12/14/26
		GENOMICS		
33.	Forecast: Somatic Mosaicism across Human Tissues (SMaHT) Program: Tissue Procurement Center (R24 Clinical Trial Not Allowed); Genome Characterization Centers; National Somatic Mosaicism Commons Data Analysis & Organizational Center (UM1 Clinical Trial Not (NIH) RFA-RM-28-014 (R24) RFA-RM-28-015 (UM1) RFA-RM-28-016 (UM1) RFA-RM-28-017 (RM1)	The purpose of the SMaHT Network is to advance the discovery of biological processes and disease mechanisms mediated by somatic mutations in human tissues. The TPC will enable functional analyses of these healthy and clinically relevant tissue samples, providing critical resources to support characterization of somatic mosaicism and its role in human biology and disease. The GCCs will determine the functional consequences of somatic mutations in healthy and clinically relevant tissue samples. The Data Center will develop tools and platforms that allow SMaHT Network members and the wider clinical and research communities to investigate and use these complex datasets. The Experimental and Computational Technology Development initiative supports multidisciplinary development, optimization, validation, benchmarking, and dissemination of rigorous, cost-effective technologies for somatic mutation detection and functional interpretation. https://www.grants.gov/search-results-detail/363857 (R24) https://www.grants.gov/search-results-detail/363858 (UM1) https://www.grants.gov/search-results-detail/363859 (UM1) https://www.grants.gov/search-results-detail/363860 (RM1)	TBD	Estimated post date: 5/1/27 Estimated due date: 7/1/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT & DATA (1)		
34.	Childhood, Adolescent and Young Adult Cancer Data Innovation Challenge (NIH/NCI)	This Challenge seeks innovative solutions and approaches that will enrich resources (data, methods, or tools) within the CCDI Data Ecosystem, build a federated learning health system, and enable exploration, visualization, interoperability, integration and analyses to benefit the outcome of childhood and AYA cancer patients. https://www.nih.gov/challenges/childhood-adolescent-young-adult-cancer-data-innovation-challenge	Total prizes of \$17 million	Milestone 1: 11/13/26
		HIV/AIDS (4)		
35.	Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional) (NIH) RFA-AI-27-018	This NOFO supports implementation research on strategies to improve the uptake, implementation, sustainment, scale and/or spread of evidence-based prevention, treatment, and care interventions in communities in the U.S. significantly impacted by HIV. Projects should be large in scale with high potential for research and public health impact. https://www.grants.gov/search-results-detail/360873	Up to \$750,000 per year, for up to 2 years (R61) Dependent upon proposal, for up to 4 years (R33)	Multiple deadlines; NOFO open through 6/20/29
36.	Forecast: HIV Prevention and Alcohol (R61/R33 Clinical Trials Optional) (NIH/NIAAA) PAS-28-073	This NOFO will support milestone-driven research that advances innovative HIV prevention interventions from development and feasibility testing to larger-scale efficacy, effectiveness, implementation, and dissemination studies. https://www.grants.gov/search-results-detail/364013	TBD	Estimated post date: 7/7/27 Estimated due date: 9/7/27
37.	Centers for Structural Biology of HIV and Other Infectious Diseases (U54 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-28-031	This NOFO supports multidisciplinary consortia of structural biologists, microbiologists, and associated experts to solve complex biological structures related to the prevention, treatment, and cure of HIV and other infectious diseases. Centers are expected to facilitate new collaborations, leverage shared resources, offer services and resources to the research community, and train the next generation of scientists engaged in structural biology of infectious diseases. https://www.grants.gov/search-results-detail/361050	Up to \$3.5 million, for 5 years	Proposal: 5/28/27
38.	Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed) (NIH/NIMH/NIDA/NINDS) RFA-MH-27-125	The purpose of this NOFO is to identify modifiable mechanisms and therapeutic targets to address CNS complications associated with HIV. The initiative supports a phased research approach beginning with the identification of patient phenotypes characterized by convergent pathophysiological features, followed by the discovery and experimental validation of molecular mechanisms using innovative in-vitro and in-vivo models. https://www.grants.gov/search-results-detail/359657	Up to \$275,000 for up to 2 years (R21) Up to \$650,000 per year, for up to 3 years (R33)	Multiple deadlines; NOFO open through 10/28/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE (10)		
39.	BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response (HHS/ASPR) 75A50126R00001_RFP_NPIVS_27	BARDA has a long-standing Vaccine Medical Countermeasures (MCMs) for Pandemic Influenza Preparedness and Response Program that ensures a constant state of pandemic readiness by enabling the rapid production of influenza vaccines and adjuvants by manufacturers of FDA-licensed vaccines in the event of a public health emergency. BARDA seeks Contractor(s) to support the continuation of this program. https://sam.gov/workspace/contract/opp/d547606225884278817f5008d9a07e99/view	Minimum of \$50,000	Proposal: 11/20/26
40.	2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases (NIH/NIAID) HHS-NIH-NIAID-BAA2026-1	This BAA is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for infectious diseases in three Research Areas. Research Area 001 - Vaccine Candidates: The objective is to develop vaccine candidates through an early phase clinical trial that use a needle free route of delivery to protect against infections caused by viral pathogens. Research Area 002 - Therapeutic Candidates: The objective is to develop safe, effective, new therapeutic products that will improve patient outcomes against serious infectious diseases for which there are no approved therapeutics, or for those that are refractory to treatment despite appropriate antimicrobial therapy or due to pathogen resistance. Research Area 003 - In Vitro Diagnostics The objective is to develop innovative, technology platforms that will speed detection and identification of infectious viruses covering a broad panel of virus families, including viruses causing acute infections as well as those causing chronic infections. https://sam.gov/workspace/contract/opp/5f75330f42ee4145990fe6a51a3dc84e/view	Dependent upon proposal and available funds	Proposal: 12/8/26
41.	Immune Drivers of Autoimmune Disease (NIH/NIAID) RFA-AI-28-011	This network aims to understand the earliest steps and triggers leading to autoimmunity and flare in humans, with the vision of ultimately preventing autoimmune disease. Priorities include discovering pre-clinical immune mechanisms, developing autoimmunity risk and staging prediction tools and biomarkers, building preclinical cohorts, leveraging remote recruitment and sampling, and artificial intelligence (AI)/big data. This complex, sustained collaboration relies on shared infrastructure to identify common triggers, pathways, and prevention opportunities. https://www.grants.gov/search-results-detail/363942	Total funding of \$3.6 million	Estimated post date: 2/26/27 Estimated due date: 6/11/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
42.	Forecast: Partnerships for Advancing Development of Diagnostics for Infectious Diseases (NIH/NIAID) RFA-AI-28-017	NIAID seeks to advance its mission by supporting partnerships for translational development of a diagnostic test that has demonstrated proof-of-concept. Novel diagnostics are needed to implement treatment strategies, evaluate vaccines and identify infectious disease outbreaks, but too often, early diagnostic breakthroughs are not being translated into successful commercial products. The goal is to align investigators with experienced industry partners early in the development process, to enable early de-risking and ensure that the end-product will be fit for purpose. https://www.grants.gov/search-results-detail/363944	Total funding of \$10 million	Estimated post date: 7/23/27 Estimated due date: 10/14/27
43.	Forecast: Centers for Research on Neglected Infectious Diseases (NIH/NIAID) RFA-AI-28-020	Neglected infectious diseases (NIDs) comprise a diverse and understudied group of communicable viral, bacterial, parasitic, and fungal infections that cause substantial morbidity, mortality, and long-term health consequences worldwide. This new research program will emphasize the epidemiology, pathogenesis, diagnosis, treatment, and prevention of communicable parasitic NIDs in endemic regions and build sustainable in-country research capacity and expertise. https://www.grants.gov/search-results-detail/364027	Total funding of \$4.2 million	Estimated post date: 3/25/27 Estimated due date: 6/15/27
44.	Forecast: The Role of the Innate Immune System in the Pathogenesis of Type 1 Diabetes (NIH/NIAID) RFA-AI-28-029	This NOFO will support studies focused on the involvement of the innate immune system in the initiation of Type 1 diabetes (T1D). This initiative directly aligns with the first goal of the congressionally mandated Special Diabetes Program, which is to identify the genetic and environmental causes of T1D. By engaging multidisciplinary teams with expertise in innate immunity and beta-cell biology, the program aims to elucidate how innate immune components interact with pancreatic tissues and beta cells. The program will leverage the use of new approach methodologies (NAMs) to precisely define the timing and impact of environmental perturbations that activate innate immune pathways. https://www.grants.gov/search-results-detail/363943	Total funding of \$15 million	Estimated post date: 7/15/27 Estimated due date: 10/13/27
45.	Pilot Projects to Enhance the Human Virome Program (R03 Clinical Trials Not Allowed) (NIH Common Fund) RFA-RM-27-024	The purpose of this NOFO is to support small pilot projects that extend the goals of the HVP, including further validating, improving, and complementing existing and newly developed tools from the HVP program by leveraging human specimens collected from the cohorts under the program; samples from animals to promote the refinement, utilization, and translation of these tools to better serve the goals of the HVP program; expanding existing cohorts and/or biospecimen sampling sites for virome characterization; developing tools, assays, and methods to study the human virome; and defining functional interactions between the human virome and host. https://www.grants.gov/search-results-detail/361431	Up to \$100,000 per year, for up to 2 years	Multiple deadlines; NOFO open through 10/22/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
46.	Forecast: Protection Before Day One Vaccine (PBD1) (BARDA/RRPV) RFI-26-o8-PBD1	The purpose of this RPP is to solicit proposals for the development and advancement of Before Day One influenza vaccine candidates. BARDA seeks to advance broadly protective influenza vaccines capable of providing routine seasonal protection while also providing meaningful cross-protection against influenza viruses with pandemic potential. https://www.rpv.org/solicitation/rfi-protection-before-day-one-vaccine-advancing-broadly-protective-seasonal-influenza-vaccines-with-pandemic-coverage/	Total funds of \$142 million, for up to 5 years	Proposers' Conference: 11/4/26
47.	Forecast: New Vaccine Platforms (NVP) Program v2 (BARDA/RRPV) RRPV 26-05-NVP	The New Vaccine Platforms (NVP) Program aims to identify new vaccine platforms for the BARDA medical countermeasure (MCM) portfolio and advance them through a staged capability demonstration to identify technologies that (1) are safe; (2) are effective across multiple infectious disease threats from different pathogen families; and (3) enable efficient development and manufacturing. In-scope platform technologies notionally include protein, viral vector, and bacterial vector-based approaches that have demonstrated manufacturing of Phase 1 clinical trial material (CTM). https://sam.gov/workspace/contract/opp/b6d47be754344b59b6518daa61c750d1/view	Total funds of \$160 million, for up to 10 years	TBD
48.	SMART Antiviral Prize (BARDA/VITAL)	The goal of this competition is to advance the development of novel antivirals that strengthen the therapeutic pipeline and address gaps in strategic preparedness in partnership with innovators offering creative solutions. The SMART Antiviral Prize focuses on supporting the development of antivirals with broad-spectrum activity against members of the Togaviridae and/or Flaviviridae families. There are currently no FDA-approved broad-spectrum antivirals for any viruses within these families—which include dengue, Zika, West Nile, and Chikungunya. https://vitalhubhealth.com/smart-antiviral-prize/	Up to \$7.5 million (Stage 1)	Declaration of intent: 11/1/27 Proposal: 2/29/28
		MATERNAL AND PEDIATRIC HEALTH (2)		
49.	Forecast: National Breastfeeding Support, Implementation, and Hospital Quality Improvement Initiative (CDC/NCCDPHP) CDC-RFA-DP-27-0063	The NOFO will support three complementary components to (1) engage national, state, and community partners; (2) provide training and technical assistance to funded recipients and healthcare organizations to use data, conduct quality improvement, and support healthcare referral networks; and (3) support U.S. and territorial maternity hospitals to safely implement and sustain evidence-based breastfeeding-supportive maternity care. https://www.grants.gov/search-results-detail/363978	Total funding of \$21.5 million	Estimated post date: 1/25/27 Estimated due date: 3/26/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MATERNAL AND PEDIATRIC HEALTH		
50.	Forecast: Collaborative Centers in Children's Environmental Health Research and Translation (P2C Clinical Trial Optional) (NIH/NIEHS) RFA-ES-28-004	Through external collaboration with the children's environmental health community, the Centers will protect and improve children's health by developing and testing new scientific questions and public health interventions/strategies with an eye towards translation; and mentoring a pipeline of new investigators interested in translational Children's Environmental Health (CEH). The CEHRT Centers will serve as national leaders in CEH translational research and research methodology development, with a focus on creating actionable steps to move evidence-informed biomedical children's environmental health research findings to the wider community of practice to protect children from harm and to ensure a healthy future. https://www.grants.gov/search-results-detail/363940	Up to \$750,000	Estimated post date: 11/3/26 Estimated due date: 3/2/27
		MEDICAL COUNTERMEASURES (1)		
51.	Advanced Research and Development of Medical Countermeasures Through Agile and Distributed End-to-End Drug Manufacturing (BARDA/BioMap) 26-13-EDM	APSR IBMSC is seeking to establish advanced research and development of medical countermeasures through agile and distributed drug substance and drug product manufacturing capacities. This includes establishing end-to-end manufacturing capacities under current good manufacturing practices (cGMP) and all associated regulatory filings to include drug master files (DMFs), New Drug Applications, (NDAs) and Abbreviated New Drug Applications (ANDAs). This scope also includes the use of qualified laboratories for product verification, environmental and shelf-life testing, and adherence to industry-recognized consensus standards applicable to performance and its goals. https://www.biomap-consortium.org/solicitation/request-for-project-proposals-advanced-research-and-development-of-medical-countermeasures-through-agile-and-distributed-end-to-end-drug-manufacturing/	Dependent upon proposal and available funds, for up to 2 years	Proposal: 10/21/26
		MUSCULOSKELETAL HEALTH (1)		
52.	NIAMS P30 Centers Program (P30 - Clinical Trial Not Allowed) (NIH/NIAMS) RFA-AR-28-001	The NIAMS P30 Centers Program supports Centers that provide coordinated research infrastructure, shared resources, and methodological expertise to advance basic, translational, and clinical research. These Centers are expected to integrate state-of-the-art research resources with capabilities that support clinical and translational research, including the development, testing, and dissemination of novel analytical methods, study designs, outcome measures, and data-driven approaches. https://www.grants.gov/search-results-detail/359152	Up to \$500,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 3/1/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT (1)		
53.	xTech Search 10 (DoD/Army)	The xTech Search 10 competition aims to accelerate the integration of small businesses into the Army's S&T ecosystem by facilitating research engagement opportunities with Army labs, including authorized access to the Army's organic intellectual and technical capital. Throughout the competition, participants will receive feedback from Army and DoW stakeholders and finalists will have an opportunity to participate in an xTech Accelerator, offering access to training, mentorship and transition-focused support to help align technology solutions with end users and acquisition stakeholders across the Army and broader DoW. https://xtech.army.mil/competition/xtechsearch10/	Up to \$1 million cash; up to \$6 million in Army SBIR/STTR proposals	Proposal: 10/19/26
		SUBSTANCE USE DISORDER (5)		
54.	Forecast: Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Program (U19 Clinical Trial Optional) (NIH/NIAAA) RFA-AA-28-002	The anticipated NOFO is expected to support collaborative research addressing high-priority needs in the FASD field, including improved early identification and diagnosis; development and validation of interventions; mechanistic and translational studies of prenatal alcohol exposure and alcohol teratogenesis; and approaches to reduce prenatal alcohol exposure and the incidence of FASD. https://www.grants.gov/search-results-detail/364028	TBD	Estimated post date: 7/25/27 Estimated due date: 9/25/27
55.	Forecast: NIDA Avenir Program: Fundamental Mechanistic Research in Addiction Science (NIH/NIDA) RFA-DA-28-002	NIDA is now expanding this program to support bold mechanistic research across a broader range of addiction science, including genetic, epigenetic, molecular, cellular, circuit, chemical, pharmacological, behavioral, and cognitive processes relevant to SUDs. This initiative is intended to catalyze high-risk, high-reward research and attract outstanding new investigators, including those from outside the addiction field. https://www.grants.gov/search-results-detail/363842	Up to \$375,000	Estimated post date: 2/1/27 Estimated due date: 5/26/27
56.	HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required) and BEACON Center (U2C Clinical Trial Not Allow (NIH) RFA-DA-28-011 (RM1) RFA-DA-28-012 (U2C)	The goal of the IMPOWR network is to test new and improved approaches for people who have both chronic pain and OUD. These approaches should lead to meaningful improvements in how health systems deliver care. These HEAL IMPOWR Phase II NOFOs will fund studies that combine clinical intervention research with implementation science, and a single Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center. https://www.grants.gov/search-results-detail/360048 (RM1) https://www.grants.gov/search-results-detail/360366 (U2C)	Up to \$900,000 per year, for up to 5 years (RM1) Up to \$1.5 million per year, for up to 5 years (U2C)	Proposal: 1/26/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
57.	Neural Ensembles & Used Substances (NExUS) Collaboratory: Building a Multimodal Inventory of Cell Ensembles Encoding the Effects of Addictive Substances (U01 Clinical Trial Not Allowed) (NIH/NIDA) RFA-DA-28-013	NExUS is a collaborative research program to decode how substance use experiences and addictive neurobehavioral states are represented in the brain at the level of cell populations. This NOFO seeks applications that propose systematic and scalable methods to identify, map, and analyze groups of neurons that respond to used substances. The goal is to create a comprehensive, multimodal database and use it to test hypotheses about how specific neural population activity patterns relate to behavioral states associated with substance use and substance use disorders (SUD), including intoxication, craving, and dependence. https://www.grants.gov/search-results-detail/360562	Up to \$700,000 per year, for up to 5 years	Proposal: 2/8/27
		THERAPEUTICS (2)		
58.	Forecast: Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (NIH/NIMH) RFA-MH-27-150	This NOFO will support the development of a research network to study rapid-acting psychotropic interventional drugs (RAPIDs), such as ketamine, esketamine, psilocybin, and other emerging treatments for serious mental illnesses. The primary goal is to generate actionable evidence on the clinical effectiveness, safety, and implementation of RAPIDs. The resulting evidence from this study will help determine how RAPIDs can be safely and effectively integrated into clinical care and may inform future approaches to health care delivery. https://www.grants.gov/search-results-detail/363875	Total funding of \$20 million	Estimated post date: 10/10/26 Estimated due date: 11/13/26
59.	Forecast: Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge (NIH Common Fund)	This challenge is intended to encourage new approaches to therapeutic development, especially for diseases linked to RNA dysfunction or diseases driven by difficult-to-drug proteins that may be addressed upstream at the RNA level. https://www.trdntchallenge.com/	Up to \$7.8 million in prizes	Submission window: 12/1/26-2/1/27
		TOXIC EXPOSURES (1)		
60.	Forecast: Mechanistic Toxicology of METALS: Metal Exposure, Transport, Action, Localization, and Susceptibility (RP1 Clinical Trial Not Allowed) (NIH) RFA-ES-27-009	The purpose of this NOFO is to support mechanistic research to understand how exposure to metals and metal-containing compounds alters biological processes relevant to human health. Of particular interest are studies that elucidate the absorption, distribution, transport, cellular trafficking, biological interactions, and mechanisms of action of metals, including mechanisms through which metals may alter immune homeostasis, cross the placental barrier, or gain access to and affect the central nervous system. https://www.grants.gov/search-results-detail/363861	Up to \$500,000	Estimated post date: 12/4/26 Estimated due date: 1/5/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		VISION RESEARCH (2)		
61.	NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) (NIH/NEI) PAR-28-072	The purpose of NEI's Translational Research program (TRP) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or combination therapies for any disease or disorder of the visual system. https://www.grants.gov/search-results-detail/360545	Up to \$500,000 per year, for up to 2 years (R61) Up to \$1 million per year, for up to 4 years (R33)	Multiple deadlines; NOFO open through 11/16/29
62.	2026 Regeneron® Ophthalmology Health Equity Challenge (BARDA/MATTER)	Regeneron® is committed to expanding access to care and improving health equity and outcomes by helping to remove barriers that prevent people from receiving the treatments and support they need. Through the 2026 Regeneron Ophthalmology Health Equity Challenge, Regeneron and MATTER, a premier healthcare incubator and innovation hub, aim to engage the innovator community in developing scalable solutions that help reduce disparities in care, improve care coordination and advance more equitable outcomes for patients experiencing barriers to vision care. https://matter.health/challenges/2026-regeneron-ophthalmology-health-equity-challenge/	Up to \$15,000 and mentorship	Proposal: 11/22/26





Recurring Opportunities

October 11, 2026

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
63.	Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-103	RSO is interested in innovations that take a systems level approach in areas including, but not limited to, systems biology, data systems, biophysical systems, health IT systems, sociotechnical systems, health-related systems engineering, and other systems with the potential to improve health outcomes. https://sam.gov/workspace/contract/opp/36eb58892e1f49f897c81d87ff7a95fe/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
64.	Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/workspace/contract/opp/29c3ac2ea6754d1f897f9c71204c0eea/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
65.	Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, also flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Advanced Technologies for Medical Product and Capability Distribution; and Biomanufacturing Innovations. https://sam.gov/workspace/contract/opp/c79dfo57a7e44d2cb3072e4ce3307422/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
66.	Proactive Health Office (PHO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/workspace/contract/opp/a5b72db5139040f8b2a1dcc2d2c96733/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (4)		
67.	Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS) FA238424S2233	CHEERS MAA is intended to provide a comprehensive strategy for AFRL/RH and USAFSAM's range of S&T, allowing for progression from basic research to technology maturation and transition. Areas of interest include: Aerospace Medicine and Physiology; Public Health and Preventative Medicine; Occupational Medicine and Bioenvironmental Engineering; and En Route Care/Expeditionary Medicine/Prolonged Field Care. https://sam.gov/opp/06fcf51457dc4361856ae1f691c70194/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis
68.	AFRL/RX Functional Materials Open BAA FA8650-22-S-5002	The Functional Material Open BAA seeks to exploit innovative functional materials that enable new warfighting capabilities, significantly improve the effectiveness of warfighters and their current and future systems and solve urgent operational needs. The Biomaterials Materials and Processes (BM&P) Research area seeks to accelerate materials development, protect assets from the environment, and enable airman performance. This research area harnesses materials and processes competencies in soft matter materials characterization, molecular and synthetic biology, microbiology, biochemistry, bioinformatics, machine learning, multiscale modeling, bioelectronics, bio- functionalization, and biological engineering to create materials not easily achievable through traditional chemical synthesis or additive manufacturing. https://sam.gov/opp/2fadbd41c2700409c993a8c308c6f5120/view	Dependent upon proposal and award mechanism	White paper: 10/28/28
69.	Research Interests of the Air Force Office of Scientific Research FA9550-26-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Chemistry and Biological Sciences Team is responsible for research activities in chemistry and biological sciences. The focus is on complex materials, microsystems and structures and well as systems of a biological nature by incorporating hierarchical design of mechanical and functional properties from the nanoscale through the mesoscale, ultimately leading to controlled well- understood chemistry/biochemistry, and material or structural behavior capable of dynamic functionality and/or performance characteristics to enhance mission versatility. https://grants.gov/search-results-detail/362681	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
70.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY (10)		
71.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29
72.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/e7c3faad3433434aaf41a5eb5ce11920/view	Dependent upon proposal	Proposals accepted on a rolling basis through 12/31/2060
73.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
74.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
75.	Medical CDID BAA MED CDID	MED CDID invites innovative proposals that allow future Army medical units to efficiently and effectively clear the battlefield (evacuation of wounded, ill, and injured), maximize return to duty, and overcome contested logistics (medical resupply). https://vulcan-sof.com/login/ng2/submission?collectionUuid=5417cc3c-2b60-446a-addf-cobe38cd0b1	Dependent upon proposal	White papers accepted through 12/31/2030



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
76.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; view the full list of research topics . https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
77.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
78.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
79.	Basic and Applied Research at the US Army Combat Capabilities Development Command - Soldier Center W911QY-25-R-0023	The Soldier Center is seeking solutions in the following scientific and technical areas: Combat Feeding & Equipment; Soldier Protection & Survivability; Modeling & Simulation; Human Performance & Biomechanics; Expeditionary Maneuver Support; Aerial Delivery; and Simulation & Training Technology. https://sam.gov/opp/e85e373d22ef47018b0336fc6a258002/view	Dependent upon proposal	Concept papers accepted on a rolling basis until 2/27/30
80.	BAA for Chemical, Biological, Radiological, Nuclear, and Explosive Defense Efforts W911SR-24-R-DEVB	DEVCOM CBC's mission is to provide innovative chemical, biological, radiological, nuclear and explosive (CBRNE) defense capabilities to enable the Joint Warfighters' dominance on the battlefield and interagency defense of the homeland. Mission areas include: Sensor technologies and biomaterials; Biological point detection; Chemical point detection; Early warning and detection; Collective protection; Respiratory protection; Decontamination; CBRN countermeasures; and Chemical biological advanced materials and manufacturing science. https://sam.gov/opp/85b4747beec740979ac430ee987bda8c/view	Dependent upon proposal and award mechanism	Preproposals accepted through 8/20/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BARDA (2)		
81.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/workspace/contract/opp/8170c4735df64714adb2d1f8ce8671b1/view	Dependent upon proposal	Proposal: 9/25/28
82.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	All AOIs are currently closed. No initial awards will be executed. Eligible +Phase submissions will still be accepted and reviewed in accordance the process outlined the EZBAA and corresponding AOI. https://sam.gov/opp/6684d4a2734047d58d6cbf7e50bdd00a/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (3)		
83.	Expedited Research Innovation System (ERIS) DARPA-PS-25-05	DARPA seeks to obtain solutions or capabilities that deliver breakthrough technological advancements that are new as of the date of submission; or technologies, processes, research or methods. Topics include: Advanced technologies for defense against potential chemical and biological threats, human-made or naturally occurring; Advanced technologies for the improved resilience of US operations throughout the prepare, deployment, execute, and return cycle; and Development of groundbreaking methods and metrology for complex, emergent, and adaptive systems, going beyond the limitations of current reductive scientific methods. https://sam.gov/opp/4f1cbdbab2a1433081746c9a7ec01bca/view	Dependent upon proposal and award mechanism	Proposal: 7/31/27
84.	Biological Technologies BAA HR001124S0034	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Combat Casualty Care; Human Performance; Materials, Sensors, Processing; Agricultural and Environmental; Security, Safety, and Surveillance; and Biomedical and Biodefense. https://sam.gov/workspace/contract/opp/8d403582edfd409795560247e8d229b7/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis
85.	Defense Sciences Office, Office-wide HR001126S0015	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Materials, Manufacturing, & Structures; Sensing and Measurement; Math, Computation, and Processing; Complex, Dynamic, and Intelligent Systems. https://sam.gov/opp/b77f1caefb244d1193ded7f6187ede52/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 8/27/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY (4)		
86.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E : • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/workspace/contract/opp/d5bcd60592c84adf908c5c1ca747bc4e/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
87.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
88.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness. https://sam.gov/opp/7a98bf70ac2a49c8b8eod71abbc93750/view	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29
89.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration. https://www.grants.gov/search-results-detail/356612	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2034



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEPARTMENT OF ENERGY (1)		
90.	FY 2027 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003665	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature’s mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. Each of the programs in SC supports research probing the most fundamental disciplinary questions. https://www.grants.gov/search-results-detail/363993	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/27
		NATIONAL SCIENCE FOUNDATION (3)		
91.	Small Business Innovation Research / Small Business Technology Transfer Phase I, Phase II, Fast-Track Programs SBIR/STTR: Developing Deep Technologies that Advance U.S. Competitiveness and Security NSF 26-510	The NSF SBIR/STTR programs invest in start-ups and small businesses to turn high-risk, high-impact research into market-ready innovations. These programs aim to advance innovation by investing in the development of critical and emerging technologies that yield market-ready or commercializable outputs, all the while harnessing the full geography of American innovation and building a competition-ready workforce. https://www.nsf.gov/funding/opportunities/small-business-innovation-research-small-business-technology/nsf26-510/solicitation	Up to \$305,000, for up to 18 months (Phase I) Only NSF Phase I SBIR/STTR awardees are permitted to submit a Phase II proposal	Project pitches accepted on a rolling basis; full proposal due 11/4/26
92.	Small Business Innovation Research / Small Business Technology Transfer Phase I, Phase II, Fast-Track Programs : A Pilot Emphasis on Scientific Instrumentation NSF 26-511	The NSF SBIR/STTR and Fast-Track programs assist startups and small businesses in developing next-generation scientific instrumentation to support the S&E enterprise. These programs aim to spur innovation by investing in the development of critical and emerging technologies that advance basic science, innovation, and commercialization, thereby making entirely new fields of scientific discovery possible. https://www.nsf.gov/funding/opportunities/small-business-innovation-research-small-business-technology-0/nsf26-511/solicitation	Up to \$305,000, for up to 18 months (Phase I) Only NSF Phase I SBIR/STTR awardees are permitted to submit a Phase II proposal	Project pitches accepted on a rolling basis; full proposal due 11/4/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NATIONAL SCIENCE FOUNDATION		
93.	Engineering (ENG): Chemical, Bioengineering, Energy, and Transport Systems (CBET) NSF 26-518	NSF ENG supports foundational engineering research for chemical, bioengineering, energy, and transport systems through the following programs: EBBS supports foundational engineering research on platforms, devices, organisms, tissues, and processes that advance knowledge and control of biological functions. TP supports foundational engineering research to understand, model, and control the transport of mass, momentum, energy, and species across multiple scales. CPS supports foundational engineering research in chemical and biochemical processes for chemicals, fuels, energy, and materials. EWRE supports foundational engineering research to manage energy, water, minerals, and material resources. https://www.nsf.gov/funding/opportunities/engineering-eng-chemical-bioengineering-energy-transport/nsf26-518/solicitation	Dependent upon proposal, for up to 5 years	Proposals accepted anytime
		NAVY (2)		
94.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://sam.gov/workspace/contract/opp/oefe2fde0926428f8ecc073fc7b5d9/view	Dependent upon proposal	Proposals accepted on a rolling basis until 12/31/26
95.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/workspace/contract/opp/oc6f40ff4b65423c821921aa8b94a62e/view	Dependent upon proposal and award mechanism	White papers accepted through 12/30/26
		OFFICE OF THE UNDERSECRETARY OF DEFENSE (1)		
96.	OUSD(R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM) HQ003425BOTA1	OUSD(R&E)'s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain. https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE (4)		
97.	Broad Pragmatic Studies Funding Announcement -- Cycle 1 2027	PCORI seeks to fund patient-centered CER comparing two or more alternatives, each of which has established efficacy and/or is in widespread use. PCORI is interested in research that fills pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader healthcare community make informed decisions about their health care and health outcomes. Applicants for the 2027 BPS PFA may select up to three of PCORI's Topic Themes; or ""Other."" Cycle 1 SAEs include: Optimizing Treatment and Symptom Management to Reduce Toxicities and Improve Patient-Centered Outcomes in Cancer Patients; Serious Mental Illness Prevention, Care and Treatment; Improving Mental Health and Substance Use Outcomes for Pregnant and Postpartum Populations; and Enhancing support services to improve mental health and address stigma experienced by individuals with sensory health conditions, their families and care partners. https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-1-2027	Up to \$12 million, for up to 5 years Dependent upon award mechanism	System opens: 11/17/26 Letter of intent: 1/6/27 Proposal: 5/4/27
98.	Phased Large Awards for Comparative Effectiveness Research -- Cycle 1 2027	PCORI is interested in research that aims to fill pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader health and healthcare community make informed decisions about their health care and health outcomes. Applicants must address PCORI's Foundational Expectations for Partnerships in Research when applying for PCORI research funding, developing project and engagement plans for awarded projects and reflecting on engagement during a project to improve and strengthen engagement over time. https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-pcori-funding-announcement-cycle-1-2027	Up to \$22 million, for up to 6.5 years	System opens: 11/17/26 Letter of intent: 1/6/27 Proposal: 5/4/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE		
99.	Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research PCORI Funding Announcement – Cycle 1 2027	PCORI seeks to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by CER studies. For the Cycle 1 2027 Methods PFA, PCORI has identified the following programmatic priority areas that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by patient-centered CER studies: Methods To Support the Use of Patient-Centered Measurement in Patient-Centered CER; Methods To Support the Use of Real-World Data (RWD) in Multi-Site Patient-Centered CER; Methods To Improve the Use of Artificial Intelligence (AI) and Machine Learning (ML) in Patient-Centered CER; and Methods To Improve Study Design in Patient-Centered CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-1-2027	Up to \$750,000, for up to 3 years	System opens: 11/17/26 Letter of intent: 1/6/27 Proposal: 5/4/27
100.	Advancing the Science of Engagement in Research PCORI Funding Announcement – Cycle 1 2027	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes of engagement in research; Techniques that lead to effective engagement in research; and How effective engagement techniques should be modified and resourced for different contexts, settings, and communities. It will solicit applications that focus on: Development and validation of measures to capture structure/context, process and outcomes of engagement, for both stakeholders and investigators; and Development and/or testing of engagement methods to generate evidence on the most effective approaches for engagement in research and how effectiveness varies by context. https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-1-2027	Up to \$1.5 million, for up to 3 years	System opens: 11/17/26 Letter of intent: 1/6/27 Proposal: 5/4/27





Terms

AoI: Area of Interest
BAA: Broad Agency Announcement
FOA: Funding Opportunity Announcement
IC: NIH Institutes and Centers
NOFO: Notice of Funding Opportunity
NOSI: Notice of Special Interest
PI: Principal Investigator
RFI: Request for Information
RFP: Request for Proposal
SBIR: Small Business Innovation Research
SDOH: Social Determinants of Health
STTR: Small Business Technology Transfer
TRL: Technology Readiness Level

Agencies

ARPA-H: Advanced Research Projects Agency for Health
ASPR: Administration for Strategic Preparedness and Response
BARDA: Biomedical Advanced Research and Development Authority
CDC: Centers for Disease Control and Prevention
CDMRP: Congressionally Directed Medical Research Programs
DARPA: Defense Advanced Research Projects Agency
DHA: Defense Health Agency
DoD: Department of Defense
FDA: U.S. Food and Drug Administration
MTEC: Medical Technology Enterprise Consortium
NIH: National Institutes of Health
NSF: National Science Foundation
PCORI: Patient-Centered Outcomes Research Institute
USAMRDC: U.S. Army Medical Research and Development Command
USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases
USSOCOM: United States Special Operations Command

GBG Acronyms

Updated Monthly

October 11, 2026

<https://www.g2gconsulting.com/gbg-reporting-service/>

NIH Institutes and Centers

CC: NIH Clinical Center
CIT: NIH Center for Information Technology
CSR: NIH Center for Scientific Review
FIC: Fogarty International Center
NCATS: National Center for Advancing Translational Sciences
NCCIH: National Center for Complementary and Integrative Health
NCI: National Cancer Institute
NEI: National Eye Institute
NHGRI: National Human Genome Research Institute
NHLBI: National Heart, Lung, and Blood Institute
NIA: National Institute on Aging
NIAAA: National Institute on Alcohol Abuse and Alcoholism
NIAID: National Institute of Allergy and Infectious Diseases
NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases
NIBIB: National Institute of Biomedical Imaging and Bioengineering
NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDA: National Institute on Drug Abuse
NIDCD: National Institute on Deafness and Other Communication Disorders
NIDCR: National Institute of Dental and Craniofacial Research
NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases
NIHES: National Institute of Environmental Health Sciences
NIGMS: National Institute of General Medical Sciences
NIMH: National Institute of Mental Health
NIMHD: National Institute on Minority Health and Health Disparities
NINDS: National Institute of Neurological Disorders and Stroke
NINR: National Institute of Nursing Research
NLM: National Library of Medicine

Join the private GBG Zoom Meeting:

<https://uso6web.zoom.us/j/84805237473?pwd=asVtAom6IstPhasBPHxZ5nan1xusxL1>

Meeting ID: 848 0523 7473

Passcode: 608981

